



Curriculum Vitae

Omid Moradi, PharmD

Board Certified Clinical Pharmacist (BCCP)

Version May 2025



OMID MORADI



EMAIL Address:

O_MORADI@OUTLOOK.COM



Phone Numbers:

+989172118131

+989334634004



ORCID:

0000-0001-5754-535X



Google SCHOLAR Profile:

[HTTPS://SCHOLAR.GOOGLE.COM/CITATIONS?USER=C_KYS24AAAAJ&HL=EN](https://scholar.google.com/citations?user=C_KYS24AAAAJ&hl=en)

PERSONAL INFORMATION

Date of birth: 2/29/1992

Place of Birth: Arak, Iran

Marital Status: Married

1st Language: Farsi

2nd Language: English

OBJECTIVE

I am highly motivated to promote my knowledge and skills in clinical pharmacy to improve healthcare services to patients in my country.

To continue my research, education, and teaching experiences in a highly dedicated organization/university in clinical pharmacy and pharmacy practice.

EDUCATION & REGISTERED COURSES

BOARD-CERTIFIED CLINICAL PHARMACIST

March 2021

School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

CLINICAL PHARMACY RESIDENCY

2017 - 2021

School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

DOCTOR OF PHARMACY (PharmD)

2011 - 2017

School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

MBA PHARMA COURSE

2022 - 2023

Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

CURRENT POSITIONS

1. Assistant Professor, Department of Clinical Pharmacy, Shiraz University of Medical Sciences, Hormozgan, Iran.
2. Member of Iranian Clinical Pharmacists Association, Tehran, Iran.
3. Member of Board of Trustees in Pharmaceutical Strategic Studies Office, Shiraz University of Medical Sciences, Shiraz, Iran.



HONORS / AWARDS

1. 5th (national-wide) and 2nd (region-wide) rank in Basic Science exam, 2014.
2. Member of Shiraz University of Medical Sciences Exceptional Talents Office, 2015-2017.
3. Member of Iran's National Elites Foundation, 2015-2016.
4. Awarded from Professor Malek Zadeh (Deputy of Research and Technology, Ministry of Health and Medical Education) to be honored for holding the 19th Iranian Pharmacy Students Seminar, 2015.
5. Elected student, 13th Festival for Privileged Students, Shiraz University of Medical Sciences, Shiraz, Iran, 2013.
6. Elected student, 14th Festival for Privileged Students, Shiraz University of Medical Sciences, Shiraz, Iran, 2014.
7. 3rd in rank, Poster Presentation, Personalized Drug Therapy congress, 10th Iranian Clinical Pharmacy Congress, Tehran, Iran, 2019.
8. 1st in rank, Clinical Pharmacy Residency Promotion Exam part 1, Shahid Beheshti University of Medical Sciences 2018-2019.
9. 1st in rank, Clinical Pharmacy Residency Promotion Exam part 2, Shahid Beheshti University of Medical Sciences 2019-2020.
10. 2nd in rank, Clinical Pharmacy Board Exam, Shahid Beheshti University of Medical Sciences, 2021.
11. Top cited article 2021-2022, Inflammation immunity and disease, Wiley, 2022.

RESEARCH


1. Pharm.D. Thesis:



Evaluation of the Pattern and Associated Factors to Immunosuppressive Medication Regimen Adherence and Potential Drug-Drug Interaction Outbreak in Renal Transplant Recipients in Shiraz. [IR.SUMS.REC.1398.519]

2. Residency Thesis:

A Randomized, Multi-centric, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Bromhexine, a serine protease [TMPRSS2] blocker, to prevent COVID-19. [IRCT20120703010178N22]

3. Research Projects and Thesis: [as correspondence/contributor]

1. The Effects of Administration of Vitamin E on Colistin Associated Nephrotoxicity in Treatment of Drug Resistance Gram Negative Bacterial Infections, A Clinical Trial. [IRCT20130917014693N8] [Contributor]
 2. Efficacy and Safety of Cyclophosphamide versus Mycophenolate Mofetil in the Induction Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis. [IR.SBMU.RETECH.REC.1398.505] [Contributor]
 3. A Review Article on De Novo Combination Use of Sirolimus and Tacrolimus Immunosuppressive Regimen in Kidney Transplant Recipients. [IR.SBMU.RETECH.REC.1397.1147] [Correspondence]
- 

- 
4. The Financial Effect of Pharmacotherapy Guidelines on Medication Utilization Cost in Governmental Hospitals in Iran. [IR.SBMU.PHARMACY.REC.1398.253] [Contributor]
 5. Evaluation the Effect of Beta Interferon in Management of Patients Infected with COVID-19. [IR.SBMU.RETECH.REC.1399.051] [Contributor]
 6. Evaluation of The Cost-Effectiveness of COVID-19 Pharmacotherapy Protocols, A Cross Sectional Study. [IR.SBMU.RETECH.REC.1399.683] [Contributor]
 7. An Investigation into Beneficial Effects of Aspirin on Clinical Outcomes in Severe Covid-19: A Retrospective Observational Study. [Contributor]
 8. Developing A Valid Questionnaire and Evaluating the Knowledge, Attitude and Practice of Pharmacists Working in Tehran Community Pharmacies Regarding Calcium and Vitamin D Supplements. [IR.SBMU.RETECH.REC.1399.1188] [Correspondence]
 9. The Effect of Pharmacy Education on Knowledge, Attitude and Practice of Thalassemia Major in Educational Pharmacy. [IR.SBMU.RETECH.REC.1399.1189] [Correspondence]
 10. The Effects of Pharmacist Education on The Knowledge of Multiple Sclerosis Patients Regarding Their Medications. [IR.SBMU.RETECH.REC.1399.1309] [Correspondence]
 11. Efficacy of Pharmacist Educational Intervention on Practice in Symptoms of Patients with Vaginal Discharge. [Correspondence]
 12. Assessing the Clinical Outcome of Pharmacist Consultation on Controlling the Symptoms of Patients with Common Upper Respiratory Disorders in Community Pharmacy. [Correspondence]
 13. Evaluation of The Efficacy and Safety of Favipiravir for the Treatment Of COVID-19 Among Inpatient Children. [Contributor]
 14. The effect of pharmacist-led patient education on medication knowledge in patients with multiple sclerosis. [IR.HUMS.REC.1400.416] [Correspondence]
 15. Evaluation of treatment adherence in patients with multiple sclerosis receiving oral medications, a cross-sectional study [IR.HUMS.REC.1402.386] [Correspondence]
 16. Evaluation of treatment adherence in patients with multiple sclerosis receiving self-injectable drugs including interferon alpha, interferon beta, and glatiramer acetate, a cross-sectional study. [IR.HUMS.REC.1402.399] [Correspondence]
 17. Epidemiology of cardiovascular risk in chronic kidney disease patients: Results from the FASA Cohort study. [IR.HUMS.REC.1402.397] [Correspondence]
 18. Evaluation of the association of the statin use and decline in renal function of patients with chronic kidney disease: Results from the FASA Cohort study. [IR.HUM IR.HUMS.REC.1402.215 S.REC.1402.398] [Correspondence]
 19. Evaluating the effect of atorvastatin on cardiovascular events in type 2 diabetes patients and correlation with triglyceride/glucose index, a cohort study. [IR.HUMS.REC.1402.215] [Correspondence]
- 



20. The effect of pregabalin on sedation of patients undergoing mechanical ventilation in the intensive care unit of Shahid Mohammadi Hospital in Bandar Abbas in 2023. [IR.HUMS.REC.1401.405] [Contributor].
21. The effect of intravenous ketamine addition to methadone for pain control in opium addicts after major surgeries in the intensive care unit of Shahid Mohammadi Hospital in Bandar Abbas, A randomized controlled blinded clinical trial in 2023. [IR.HUMS.REC.1401.404] [Contributor]
22. Drug utilization evaluation of human albumin solution in Payambar Azam Teaching Medical Center. [IR.HUMS.REC.1401.219] [Correspondence]
23. Evaluation of drug-drug interaction in outpatient prescription of children's hospital pharmacy in Bandar abbas [IR.HUMS.REC.1401.220] [Contributor]
24. Evaluation of the pattern and influencing factors of adherence to treatment in patients using mycophenolate mofetil and mycophenolate sodium, a multicenter cross-sectional study. [IR.HUMS.REC.1402.480] [Correspondence].

4. Publications:

I. Published online/Accepted manuscript:

1. Zia-behbahani M, Barzegar A, **Moradi O**, Faghihi M, Khamooshi M, Khademian S, Zarshenas MM, Mohagheghzadeh A. Ethnopharmacological Study of Medicinal Plants Used for Treating Dysuria: A Collection from Traditional Markets in Shiraz. *Complement Med Res*. 2018;25(4):240-248. doi: 10.1159/000486641.
2. **Moradi O**, Karimzadeh I, Davani-Davari D, Shafikhani M, Sagheb MM. Drug-drug interactions among kidney transplant recipients in the outpatient setting. *Int J Organ Transplant Med*. 2020;11(4):185-195. PMID: 33335699.
3. **Moradi O**, Karimzadeh I, Davani-Davari D, Shafiekhani M, Sagheb MM. Pattern and Associated Factors of Adherence to Immunosuppressive Medications in Kidney Transplant Recipients at A Referral Center in Iran. *Patient Prefer Adherence*. 2019;13:729-738. doi: 10.2147/PPA.S198967.
4. Ziaie S, **Moradi O**, Saffaei A. Comment on: Efficacy and Safety of Mycophenolate Mofetil versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis. *Iran J Kidney Dis*. 2019; 13(5):346. PMID: 31705754.
5. Abbasinazari M, Hosseinpanah F, **Moradi O**, Soleimani S. Evaluation of the Pattern of Adherence to Levothyroxine Use and Effect of Education via Pamphlet in Hypothyroidism Patients. *Journal of Medical Council of Islamic Republic of Iran*. 2018; 36(3):168-172. [In Persian]. URL: <http://jmciri.ir/article-1-2854-en.html>.
6. Kharazmkia A, Ziaei S, Ahmadpoor P, **Moradi O**, Khoshdel A. A Triple-blind Randomized Controlled Trial on Impacts of Pioglitazone on Oxidative Stress Markers in Diabetic Kidney Transplant Recipients. *Shiraz E-Med J*. 2019; Online ahead of Print; 21(11): e98656. doi: 10.5812/semj.98656.
7. **Moradi O**, Sahraei Z, Asadi S. From Bench to Bedside: Colistin Nephrotoxicity and Vitamin E. *Clin Microbiol Infect Dis*. 2019; 4:1-2. doi: 10.15761/CMID.1000161.

8. Shojaei L, Aghakhani K, **Moradi O**. Epidemiology of Burn Patients Admitted to Intensive Care Unit of Motahari Hospital in Tehran (2008-2013). *Journal of Medical Council of Islamic Republic of Iran*, 2019;37(2):88-93. [In Persian]. URL: <http://jmciri.ir/article-1-2906-en.html>.
9. Noori M, Salamzadeh J, Hajiesmaeili M, Rezaeimirghaed O, **Moradi O**, Saffaei A, Sahraei Z. Evaluation of the Appropriateness of Albumin Usage in a Teaching Hospital in Iran: The Impact of Clinical Pharmacist Intervention. *Shiraz E-Med J*. 2021;22(4):e102178. doi: 10.5812/semj.102178.
10. Shabani, M, Shokouhi, S, **Moradi, O**, Saffaei, A. and Sahraei, Z. Tocilizumab Administration in Patients With SARS-Cov-2 Infection: Subcutaneous Injection vs Intravenous Infusion. *J Med Virol*. 2020;93:69-70. doi: 10.1002/jmv.26124
11. **Moradi O**, Shojaei S, Koucheh M, Miri M, Sistanizad M. Interleukin-I Receptor Antagonist in the Treatment of COVID-19 Induced Cytokine Storm. *J Cell Mol Anesth*. 2020;5(3). doi: 10.22037/jcma.v5i3.30630.
12. Khalili S, **Moradi O**, Kharazmi A, Raoufi M, Sistanizad M, Shariat M. Comparison of COVID-19 Mortality Rate and Pulmonary Involvement in Diabetic and Non-Diabetic Population, A Cohort Study. *Can J Diabetes*. 2020; 45(6):524-530. doi: 10.1016/j.cjcd.2020.10.014.
13. Alavi I, Hatami F, Rabiei MM, Pourhoseingholi MA, **Moradi O**, Shokouhi S, et al. An investigation into the beneficial effects of high-dose interferon beta I-a, compared to low-dose interferon beta I-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled I trial. *Trials Journal, BMC*. 2020; 21(1):880. doi: 10.1186/s13063-020-04812-2.
14. Sahraei Z, Samsami M, Barati S, **Moradi O**. The Effects of Vitamin E on Colistin-Induced Nephrotoxicity in Treatment of Drug-Resistant Gram-Negative Bacterial Infections: A Randomized Clinical Trial. *J Infect Chemother*. 2021;27(8):1181-1185. doi: 10.1016/j.jiac.2021.03.013.
15. Haji Aghajani, M, **Moradi, O**, Amini, H, et al. Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19. *J Med Virol*. 2021;93(9):5390-5395. doi: 10.1002/jmv.27053.
16. Haji Aghajani M, **Moradi O**, Amini H, et al. Promising Effects of Atorvastatin on Outcomes of Patients with Severe COVID-19, A Retrospective Cohort Study. *Int J Clin Pract*. 2021;75(9):e14434. doi: 10.1111/ijcp.14434.
17. Alavi Darazam I, Hatami F, Rabiei MM, Pourhoseingholi MA, Shabani M, Shokouhi S, Mardani M, **Moradi O**, et al. An investigation into the beneficial effects of high-dose interferon beta I-a, compared to low-dose interferon beta I-a in moderate to severe COVID-19: the COVIFERON II randomized controlled trial. *Int Immunopharmacol*. 2021;99:107916. doi: 10.1016/j.intimp.2021.107916.
18. Parkhideh S, Zeraatkar M, **Moradi O**, Hajifathali A, Mehdizadeh M, Tavakoli-Ardakani M. Azithromycin Oral Suspension in Prevention and Management of Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial. *Support Care Cancer*. 2021;30(1):251-257. doi: 10.1007/s00520-021-06409-0.
19. Alavi Darazam I, Shokouhi S, Mardani M, Pourhoseingholi MA, Rabiei MM, Hatami F, Shabani M, **Moradi O**, et al. Umifenovir in Hospitalized Moderate to Severe COVID-19 Patients: A Randomized Clinical Trial. *Int Immunopharmacol*. 2021;99:107969. doi: 10.1016/j.intimp.2021.107969.

- 
20. Alavi-Darazam, Forouhar K, **Moradi O**, Saffaei A, Asadi S, Sahraei Z. Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-Critically Ill Patients: A Randomized Controlled Trial. *Iran J Pharm Res.* 2022;21(1):e126555. doi: 10.5812/ijpr-126555.
21. Mahmoudi L, Asadi S, Moaref M, **Moradi O**, Izadpanah P. The Prevalence of Hypovitaminosis D in Patients with Coronary Artery disease and the Correlation of Vitamin D level with high Sensitive C-reactive Protein, A report from Southern Iran. *Int Cardiovasc Res J.* 2021. 15 (3); e119230.
22. Kharazmi A, **Moradi O**, Haghighi M, Kouchek M, Manafi-Rasi A, Raoufi M, et al. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19. *Immun Inflamm Dis.* 2022;10(2):201-208.; 10: 201-208. doi:10.1002/iid3.563.
23. Haji Aghajani M, Pourheidar E, **Moradi O**, Pourhosseingoli A, Â Taherpour N, Barootkoob A, Hassanpour R, Agah E, Mousavi SV, Sistanizad M. Comparison of the Eight Different Treatment Regimens for the Hospitalized Patients with COVID-19: A Retrospective Cohort Study. *J Cell Mol Anesth.* 2021;6(4):329-38. doi: 10.22037/jcma.v6i4.35553.
24. Mirrahimi B, Rohani P, **Moradi O**, Hemmati A. Octreotide Efficacy and Safety in Pediatric Non-variceal Upper Gastrointestinal Bleeding: A Randomized Placebo-Controlled Clinical Trial. *Iran J Pediatr.* 2022;32(2):e122344. doi: 10.5812/ijp.122344.
25. Rafiei Tabatabaei S, **Moradi O**, Karimi A, Armin S, Fahimzad A, et al. A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19. *Iran J Pharm Res.* 2022;21(1):e127034. doi: 10.5812/ijpr-127034.
26. Darazam IA, Rabiei MM, **Moradi O**, Gharehbagh FJ, Roozbeh M, Nourinia R, Hatami F, Shojaei M, Lotfollahi L. A Case of Fingolimod-associated Cryptococcal Meningitis. *Curr HIV Res.* 2022;20(4):337-342. doi: 10.2174/1570162X20666220629124225.
27. Sistanizad M, Haji Aghajani M, Haghighi M, Amini H, Pourhoseingholi A, Taherpour N, Ziaie S, Salarian S, **Moradi O**. Comparing the Characteristics of Mucormycosis Between Cases with and without COVID-19; a Cross-sectional Study. *Arch Acad Emerg Med.* 2022;10(1):e56. doi: 10.22037/aaem.v10i1.1608.
28. Haghighi M, Sistanizad M, **Moradi O**, et al. Efficacy and safety of Interferon-beta 1a in the management of the outpatients with mild to moderate COVID-19 (A preliminary study). *Inter J Health Sci.* 2022;6(S7), 6033–6041. doi: 10.53730/ijhs.v6nS7.13420.
29. Alavi I, Rabiee MM, Bahrami H, **Moradi O**, et. Al. Garcin Syndrome in A Case of Acquired Immunodeficiency Syndrome. *Clin Case Rep.* 2022 Oct 17;10(10):e6476. doi: 10.1002/ccr3.6476.
30. Tolouian R, **Moradi O**, Mulla Z D, Ziaie S, Haghighi M, et al. Bromhexine for Post-exposure COVID-19 Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial. *Jundishapur J Microbiol.* 2022;15(8):e130198. doi:10.5812/ijm-130198.
31. Sabaghian T, Raoufi M, Yaghmaei S, **Moradi O**, Alavi A, Ebrat Balkhkanlou H, Masbough F, Falsafi A, Heidari Almasi M. Roles of Clinical Features and Chest CT in Predicting the Outcomes of Hospitalized Patients with COVID-19 Developing AKI. *Iran J Kidney Dis.* 2023;1(1):9-13. PMID: 36739485.
- 

32. Sistanizad, M., Sabaghian, T., Amini, H. Hadavand F. Nabavi M, Kouckek M, Miri MM, Salarian S, Shojaei S, **Moradi O**. Sinopharm (HB02)-associated vaccine-induced immune thrombotic thrombocytopenia: a case report. *J Med Case Reports*. 17, 383 (2023). doi:10.1186/s13256-023-04086-7.
33. Asadi S, Babaei M, Fathalipour M, **Moradi O**. A Narrative Review on Smoking Cessation Pharmacotherapy. *Tobacco and Health*. 2023; 2 (4) :155-162. URL: <http://thj.hums.ac.ir/article-1-21-fa.html>.
34. Pourrezagholi F, Amini H, **Moradi O**, Ziaie S. Tacrolimus-induced cholestatic hepatotoxicity after renal transplantation: a case report. *J Med Case Reports*. 2024;18(1):116. doi: 10.1186/s13256-024-04394-6.
35. Sara Asadi, **Omid Moradi**, Hossein Amini, MReza Goodarzian, Maryam Babaei, Maral Goodarzian, et al. A Cross-Sectional Investigation on Drug-Drug Interactions in Prescriptions of Pediatric Outpatient Clinics at a Referral Center in Southern Iran. *J Compr Ped*. 2024;15(4):e144355. <https://doi.org/10.5812/jcp-144355>.

II. Books:

۱. تألیف به فارسی، خیراله غلامی، دکتر مجتبی مجتهدزاده، گروه نویسندگان. درسنامه جامع درمان شناسی، ویرایش سوم، چاپ اول ۱۴۰۲، جلد اول {شایک: ۹۷۸۶۲۲۶۵۱۱۳۱۵}.
۲. ترجمه به فارسی، راهنمای داروهای بدون نسخه رویکرد تعاملی به مراقبت از خود، ویرایش نوزدهم. موسسه انتشارات اطمینان راد.

III. Not-Peer Reviewed Publications:

۱. خیرالله غلامی، امید مرادی، سارا اسدی. "عوارض دارویی یکی از عمده ترین عوامل مرگ و میر"، روزنامه کثیرالانتشار آفتاب یزد. شماره ۵۴۸۴، تیرماه ۱۳۹۸.

2. Peer Reviews

1. Journal of Medical Virology, Efficacy and safety of dexmedetomidine for prone ventilation in elderly patients with pneumonia: A prospective, double-blind, randomized controlled study. Manuscript ID: JMV-24-21677.
2. Journal of Medical Virology, Intravenous High-dose Anakinra Drops Venous Thrombosis and Myocardial Infarction in Severe and Critical COVID-19 Patients: A Propensity Score Matched Study. Manuscript ID: JMV-23-20994.
3. The Journal of Infection in Developing Countries, Antibiotics in the treatment of scrub typhus: A network meta-analysis and cost-effectiveness analysis. Manuscript ID: 19228.
4. The Journal of Infection in Developing Countries, Side Effects of Covid-19 Vaccines Among Iranian Health Care Workers: A Retrospective Cohort Study. Manuscript ID: 17691.
5. Journal of Disease and Diagnosis, An Investigation of the Risk Factors of Osteoporosis and the Correlation between Drugs Consumption and Osteoporosis: Results of Fasa PERSIAN Cohort Study. Manuscript ID: ddj-544.

6. Journal of Disease and Diagnosis, MINI-REVIEW ON RISK-BENEFIT ASSOCIATED WITH AZITHROMYCIN. Manuscript ID: ddj-509.
7. NIMAD, Relationship between gut microbiome and serum lactate and cerebrospinal fluid concentrations in relapsing-remitting, primary progressive and secondary progressive multiple sclerosis patients. ID: 402/23578.

EXECUTIVE/EDUCATIONAL

	Explanation	Date
1	Scientific and Executive secretary of Student research committee office, Shiraz University of Medical Sciences, Shiraz, Iran	From 2011 to 2012
2	Student Member of Committee for Tracking Issues, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran	From 2012 to 2013
3	Deputy of Union and Education Council, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran	From 2013 to 2014
4	Deputy of Executive Committee, 19 th Iranian Pharmacy Student Seminar, Shiraz, Iran	October 2015
5	Member of Union and Education Council, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran	From 2014 to 2015
6	Member of Special Commission for the Advancement of Exceptional Talents, Shiraz University of Medical Sciences, Shiraz, Iran	From 2015 to 2017
7	Member of Board of Trustees in Pharmaceutical Strategic Studies Center (PSSC), School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran	From 2016-Now
8	Executive Committee, 18 th Asian Conference on Clinical Pharmacy & 9 th Iranian Clinical Pharmacist Congress, Tehran, Iran	June 2018
9	Executive Committee, 10 th Iranian Clinical Pharmacist Congress, Tehran, Iran	June 2019
10	Scientific Secretary of Student Research Committee Office, Prevention of Cardiovascular Diseases Research Center, Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran	Nov 2020-Now
11	Executive Committee, 11 th Iranian Clinical Pharmacist Congress, Tehran, Iran	Feb, 2021

PROFESSIONAL EXPERIENCE


1. Assistant professor of clinical pharmacy, Department of Clinical Pharmacy, Hormozgan University of Medical Sciences, Hormozgan, Iran.
2. Teaching experience in Internship program class for undergraduate students (Skill Laboratory), School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2018-19.

- 
3. Teaching experience in basic and clinical pharmacology for MS. Nursing students (Intensive care, Internal medicine, Emergency medicine), School of Nursing, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2018, 2019.
 4. Head, Pharmaceutical Unit Ward, Shahid Mohammadi Medical Center, Hormozgan university of medical Center, Hormozgan, Iran.
 5. Head of department, Department of Clinical Pharmacy, Hormozgan University of Medical Sciences, Hormozgan, Iran.
 6. Chief of the committee, Community Pharmacy Internship Program, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran.
 7. Teaching experience in pharmacotherapy courses, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 1st, 2nd semester 2020-2021.
 8. Teaching experience in pharmacotherapy course, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 1st, 2nd semester 2021-2022.
 9. Teaching experience in pharmacotherapy course, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 1st, 2nd semester 2022-2023.
 10. Teaching experience in pharmacotherapy course, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 1st semester 2023-2024.
 11. Teaching experience in community pharmacy internship, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 1st semester 2020-2021.
 12. Teaching experience in community pharmacy internship, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 1st semester 2021-2022.
 13. Teaching experience in community pharmacy internship, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 1st semester 2022-2023.
 14. Teaching experience in hospital pharmacy internship, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 2nd semester 2020-2021.
 15. Teaching experience in hospital pharmacy internship, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 2nd semester 2021-2022.
 16. Teaching experience in hospital pharmacy internship, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 2nd semester 2022-2023.
 17. Teaching experience in clinical pharmacy internship, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 2nd semester 2020-2021.
 18. Teaching experience in clinical pharmacy internship, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 2nd semester 2021-2022.
 19. Teaching experience in clinical pharmacy internship, School of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran, 2nd semester 2022-2023.

CONGRESS/COURSES/POSTERS/WORKSHOPS

Congress (Attendance):



- 
1. 19th Iranian Pharmacy Student Seminar, Shiraz, Iran, October 2015.
 2. 9th Iranian Clinical Pharmacists Congress, Tehran, Iran July 2018.
 3. 1st International Congress of Pharmacy Updates, Tehran, Iran Feb 2018.
 4. 10th Iranian Clinical Pharmacist Congress, Tehran, Iran, June 2019.
 5. 3rd Seminar of Infection in Transplantation and Cancer, Feb 2020.
 6. European Society of Clinical Microbiology and Infectious Diseases, Conference on Coronavirus Disease, Umifenovir in hospitalized COVID-19 patients, Sep 2020, [Abstract]
 7. 31st European Congress of Clinical Microbiology and Infectious Diseases, Fingolimod-associated Cryptococcal Meningitis: A Case Report and Literature Review, July 2021, [Abstract].
 8. 31st European Congress of Clinical Microbiology and Infectious Diseases, An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19, July 2021, [Abstract]
 9. A. POS-871 THE CORRELATION BETWEEN CHEST CT FINDINGS AND OUTCOME IN COVID-19 PATIENTS WITH AND WITHOUT ACUTE KIDNEY INJURY. *Kidney Int Rep.* 2022 Feb;7(2):S376–7. doi: 10.1016/j.ekir.2022.01.909. [Poster]
 10. 9th International Congress of Iranian Society of Organ Transplantation (IRSOT), 31 Oct- 3 Nov 2023.


Congress (As Referee):

1. 22nd Iranian Pharmacy Student Seminar, Zanjan, Iran, April 2019.
2. 24th Iranian Pharmacy Student Seminar, Tehran, Iran, April 2024.

Conferences / Workshops (Presenter)

1. Coetaneous Necrosis after Sodium Stibogluconate Injection for Cutaneous Leishmaniasis Treatment: A Rare Case Report, 10th Iranian Clinical Pharmacist Congress, Tehran, Iran, June 2019.
2. Pattern and associated factors of adherence to immunosuppressive medications in kidney transplant recipients at a referral center in Iran, 10th Iranian Clinical Pharmacist Congress, Tehran, Iran, June 2019.
3. Drug-drug interactions among kidney transplant recipients in the outpatient setting, 10th Iranian Clinical Pharmacist Congress, Tehran, Iran, June 2019.
- 4.
5. Search in Clinical Databases, UpToDate, School of Pharmacy, Hormozgan University of Medical Sciences, Hormozgan, Iran. May 2022.
6. New insights on COVID-19 pharmacotherapy, Abadan University of Medical Sciences, Jan 2022.

Courses/Workshops (Participant)

1. Good Clinical Practice, Clinical Trial Centre, Tehran University of Medical Sciences, Tehran, Iran, August 2018.
 2. Scientific writing, “How to Write a good paper”, Research Consultation Centre, Shiraz University of Medical Sciences, Shiraz, Iran, May 2017.
- 

- 
3. Search and electronic databases, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran, March 2016.
 4. Reference manager, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran, June 2016.
 5. Scientific Writing, “Thesis”, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran, November 2016.
 6. Scientific Writing, “Proposal”, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran, November 2016.
 7. Therapeutic Vancomycin Monitoring Using AUC₂₄, Sanford Guide, Sperryville, VA 22740 USA, Dec 2020.
 8. Meta-analysis Softwares, Cochrane Iran, National workshop, 24-26 July, 2021.
 9. Antimicrobial Stewardship: A competency-based approach, 30 September, 2021.
 10. Social Response in Medical Science, Hormozgan University of Medical Sciences, Hormozgan Iran, 12 Dec 2022.
 11. Evidenced-Based Teaching In Medical Sciences, Tehran University of Medical Sciences, 20 Aug 2023.
 12. Course on Nutrition in Critical illness, European Society of Intensive Care Medicine, European Accreditation Council for Continuing Medical Education, Belgium, 26-27 April, 2023.
 13. Cohort studies Design, Deputy of research and technology, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. 15-16 November 2022.
- 